基因編輯技術(shù)可針對(duì)性增強(qiáng)體細(xì)胞的靶向性，一定程度上解決了傳統(tǒng)過(guò)繼性免疫療法在腫瘤等多種疾病治療中顯露出的靶向性差等問(wèn)題。最具代表性的是嵌合抗原受體T細(xì)胞（CAR-T）免疫療法，其在血液系統(tǒng)腫瘤治療中已取得良好療效，此外，T細(xì)胞受體基因工程化的T細(xì)胞（TCR-T）、基因修飾的樹(shù)突狀細(xì)胞以及基因修飾的干細(xì)胞在多種疾病治療的臨床研究中也顯現(xiàn)了良好的安全性和有效性。目前國(guó)內(nèi)外多家研究機(jī)構(gòu)和生物公司已在基因修飾體細(xì)胞行業(yè)加速布局，相關(guān)產(chǎn)業(yè)即將進(jìn)入快速發(fā)展期，基因修飾體細(xì)胞療法的臨床轉(zhuǎn)化應(yīng)用具有廣闊前景，對(duì)目前已經(jīng)開(kāi)展疾病臨床研究的幾種基因修飾免疫細(xì)胞療法進(jìn)行總結(jié)。

The Gene editing technology could enhance the on-target of somatic cells, and partially resolve the problem of off-target of the adoptive immunotherapy in the treatment of tumors and the other diseases. One of the he most representative methods is CAR-T cell therapy, which has been achieved well curative effect in the treatment of hematological tumors. In addition, the treatment methods which include using TCR-T cells, genetically modified dendritic cells and genetically modified stem cells have also been shown well safety and effectiveness in the clinical research of various diseases. In view of this, many research institutions and biological companies in China and the other countries have accelerated their deployment in the fields of genetically modified somatic cell at now, and will be reaching a period of rapid development. The clinical transformation and application of genetically modified somatic cell therapy hold great promising in the fulture.

R926

國(guó)家科技重大專(zhuān)項(xiàng)課題——重大新藥創(chuàng)制（2016ZX09101094）；北京市科委企業(yè)技術(shù)創(chuàng)新平臺(tái)建設(shè)（Z181100000518028）